Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following...

BioMarin Pharmaceutical Inc.

Ascendis Pharma stock rallied 7% on Monday after the company reached a global settlement and license deal with BioMarin Pharmaceutical.

On August 13, Ascendis Pharma (NASDAQ:ASND) reported second-quarter results that showed how far its rare disease portfolio has come.

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for its "Artisan Small Cap Fund". A copy of the letter can be downloaded here.

In this article, we will discuss the 10 Most Profitable Growth Stocks to Buy.

Ascendis Pharma A/S (NASDAQ:ASND) Q1 2026 Earnings Call Transcript May 7, 2026Ascendis Pharma A/S beats earnings expectations. Reported EPS is $0.32, expectations were $0.21.

In this article, we discuss the Billionaire Joe Edelman's Stock Picks with Huge Upside Potential.

In this article, we will look at the 7 Best Strong Buy European Stocks to Invest In. European stocks are getting a closer look as investors search beyond the crowded parts of the U.S.